These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 30678550)

  • 21. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulating tumor mechanics with nanomedicine for cancer therapy.
    Zhao Q; Chen J; Zhang Z; Xiao C; Zeng H; Xu C; Yang X; Li Z
    Biomater Sci; 2023 Jun; 11(13):4471-4489. PubMed ID: 37221958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral lipid nanomedicines: Current status and future perspectives in cancer treatment.
    El Moukhtari SH; Rodríguez-Nogales C; Blanco-Prieto MJ
    Adv Drug Deliv Rev; 2021 Jun; 173():238-251. PubMed ID: 33774117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barrier permeation and improved nanomedicine delivery in tumor microenvironments.
    Liu J; Zhang J; Gao Y; Jiang Y; Guan Z; Xie Y; Hu J; Chen J
    Cancer Lett; 2023 May; 562():216166. PubMed ID: 37028698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
    Balasubramanian V; Liu Z; Hirvonen J; Santos HA
    Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity.
    Ryu JH; Yoon HY; Sun IC; Kwon IC; Kim K
    Adv Mater; 2020 Dec; 32(51):e2002197. PubMed ID: 33051905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
    Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing Tumor Penetration of Nanomedicines.
    Sun Q; Ojha T; Kiessling F; Lammers T; Shi Y
    Biomacromolecules; 2017 May; 18(5):1449-1459. PubMed ID: 28328191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
    Swetha KL; Roy A
    Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aptamer-guided nanomedicines for anticancer drug delivery.
    Alshaer W; Hillaireau H; Fattal E
    Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanomedicine: de novo design of nanodrugs.
    Yang Z; Kang SG; Zhou R
    Nanoscale; 2014 Jan; 6(2):663-77. PubMed ID: 24305636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
    Du JZ; Li HJ; Wang J
    Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Strategies in the Design of Nanomedicines to Oppose Uptake by the Mononuclear Phagocyte System and Enhance Cancer Therapeutic Efficacy.
    Zhou Y; Dai Z
    Chem Asian J; 2018 Nov; 13(22):3333-3340. PubMed ID: 29441706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smart Nanosystems for Overcoming Multiple Biological Barriers in Cancer Nanomedicines Transport: Design Principles, Progress, and Challenges.
    Lin G; Zhou J; Cheng H; Liu G
    Small; 2023 Jul; 19(28):e2207973. PubMed ID: 36971279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Grand challenges in nanomedicine.
    Wu LP; Wang D; Li Z
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110302. PubMed ID: 31753337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.